# Batch 3 Validation Review

Date created: 2026-06-02

Status: CANDIDATE REVIEW

Purpose: validate Batch 3 Synthetic World-Level File Construction for FI-W14 through FI-W16 against locked File Inventory v1, Synthetic World-Level File Construction Plan v1, Batch 1 locked files, Batch 2 locked files, and locked world architecture.

This validation review does not create task prompts, expected outputs, golden responses, grader guidance, AutoQC responses, submission artifacts, post-world information, or additional synthetic file rows.

## Files Constructed

| File ID | Constructed file | Locked inventory row matched | Status |
| --- | --- | --- | --- |
| FI-W14 | `FI-W14_nephrology-consultation-documentation.md` | Nephrology consultation documentation | VERIFIED |
| FI-W15 | `FI-W15_cardiology-consultation-documentation.md` | Cardiology consultation documentation | VERIFIED |
| FI-W16 | `FI-W16_endocrinology-consultation-documentation.md` | Endocrinology consultation documentation | VERIFIED |

Constructed file count: 3.

Authorized Batch 3 file IDs: FI-W14 through FI-W16.

Unauthorized synthetic files created: none.

## Locked Row Purpose Mapping

### VERIFIED

Finding: FI-W14 maps to its locked row purpose.

Evidence: the file represents AKI-on-CKD recovery, hypotension/volume risk, renal medication safety, and time-sensitive medication recommendations while reacting to FI-W12 objective trends and FI-W13 medication actions.

Impact: supports Trap #2 and Trap #5 without creating a final medication plan.

Action required: candidate review should confirm nephrology remains cautious but not anti-GDMT.

### VERIFIED

Finding: FI-W15 maps to its locked row purpose.

Evidence: the file represents HFrEF/CAD protective therapy, GDMT reintroduction concerns, and decompensation/readmission risk while acknowledging renal, potassium, intake, and blood pressure limitations.

Impact: preserves Cardiology vs Nephrology as a timing and risk-balancing friction.

Action required: candidate review should confirm cardiology remains proactive but not careless.

### VERIFIED

Finding: FI-W16 maps to its locked row purpose.

Evidence: the file represents steroid/adrenal risk interpretation, prednisone exposure concerns, source hierarchy reconstruction, and diabetes/steroid interaction without proving adrenal insufficiency.

Impact: supports Trap #1 and Endocrinology vs Primary Team without converting steroid physiology into the hidden answer.

Action required: candidate review should confirm rheumatology remains the highest-authority prednisone-history source.

## Unauthorized Content Check

### VERIFIED

Finding: no FI-W17 through FI-W22 files were created.

Evidence: Batch 3 construction created only FI-W14, FI-W15, FI-W16, and this validation review inside `worlds/korvin-merrow/synthetic-files/candidate-review/batch-3/`.

Impact: batch boundary is preserved.

Action required: do not create Batch 4 or Batch 5 files until explicitly authorized.

### VERIFIED

Finding: no task-level, supplementary, prompt, golden, grader, AutoQC, DOCX, or submission artifacts were created.

Evidence: constructed artifacts are limited to the authorized Batch 3 candidate-review files and validation review.

Impact: downstream phase boundaries remain intact.

Action required: none before candidate review.

## Temporal Validation

### VERIFIED

Finding: no post-world information is present.

Evidence: FI-W14 through FI-W16 are anchored from HD2-HD6 and contain only information available before 05/23/2026 at 18:00. No file includes discharge-day outcome, +7 information, +30 information, or later follow-up.

Impact: closed-world discipline is preserved.

Action required: none before candidate review.

## Trap Preservation Validation

### VERIFIED

Finding: Trap #1 remains active and reconstructable.

Evidence: FI-W16 applies the prednisone hierarchy but does not resolve actual pre-admission adherence, prove adrenal insufficiency, or create a final prednisone taper.

Impact: steroid source-of-truth remains a synthesis problem.

Action required: later FI-W20 and FI-W22 must not collapse this uncertainty.

### VERIFIED

Finding: Trap #2 remains active and strengthened.

Evidence: FI-W14 and FI-W15 offer competing but defensible interpretations of renal recovery, potassium risk, blood pressure reserve, GDMT reintroduction, and MAR action history.

Impact: medication restart reasoning requires reconciliation across consultants, trends, MAR actions, and hospitalist synthesis.

Action required: later discharge-facing files must not make either consultant automatically correct.

### VERIFIED

Finding: Trap #3 and Trap #5 remain distinct.

Evidence: Batch 3 consultant notes acknowledge functional/discharge context but do not create nursing, PT, OT, family, case management, or discharge-facing evidence. FI-W14 through FI-W16 support Trap #5 as consultant caveats that must be reconciled later; they do not replace buried functional/cognitive sources.

Impact: Batch 4 remains necessary for buried functional/cognitive substrate, and Batch 5 remains necessary for the visible but incomplete discharge-facing source.

Action required: preserve this split in FI-W17 through FI-W22.

### VERIFIED

Finding: Trap #4 remains active without sepsis reversal.

Evidence: FI-W16 explicitly treats infection-oriented improvement as real and clinically relevant while warning that steroid risk should not be ignored. No file says sepsis was wrong or that adrenal physiology explains everything.

Impact: mixed physiology and sepsis anchoring after partial improvement are preserved.

Action required: none before candidate review.

## Friction Preservation Validation

### VERIFIED

Finding: Cardiology vs Nephrology remains balanced.

Evidence: FI-W14 supports cautious renal/hemodynamic sequencing, while FI-W15 supports deliberate HFrEF/CAD medication reintroduction planning. Each note recognizes the other service's rationale.

Impact: neither consultant is obviously correct, careless, or final.

Action required: candidate review should compare the two notes together for symmetry and defensibility.

### VERIFIED

Finding: Endocrinology vs Primary Team remains balanced.

Evidence: FI-W16 states both that steroid risk is clinically meaningful and that adrenal insufficiency is not proven. It explicitly recognizes the primary team's defensible concern about over-attribution after infection-oriented improvement.

Impact: endocrine consultation remains interpretive rather than a hidden diagnosis reveal.

Action required: none before candidate review.

### VERIFIED

Finding: hospitalist-synthesizes-not-defers governance is preserved.

Evidence: all three consultant notes state that attending/hospitalist synthesis remains required and that consultant recommendations do not override the broader chart.

Impact: authority hierarchy and consultant disagreement remain distinct.

Action required: preserve during later discharge-facing construction.

## Source-Of-Truth Hierarchy Validation

### VERIFIED

Finding: master source-of-truth hierarchy is preserved.

Evidence: consultant files are presented as consultant documentation and specialty interpretation, not as overrides of attending documentation, verified medication reconciliation, pharmacy history, primary care documentation, family report, or patient recollection.

Impact: source channels remain separate and traceable.

Action required: none before candidate review.

### VERIFIED

Finding: prednisone-specific hierarchy is preserved.

Evidence: FI-W16 explicitly orders rheumatology attending documentation above verified medication reconciliation, pharmacy history, family report, and patient recollection.

Impact: outpatient rheumatology remains the highest-authority prednisone taper-intent source.

Action required: later files must not let endocrinology replace rheumatology as the prednisone-history source of truth.

## Batch 1 Consistency Validation

### VERIFIED

Finding: Batch 3 remains consistent with FI-W01 through FI-W07.

Evidence: FI-W14 through FI-W16 inherit the same identity, baseline context, medication provenance, prednisone uncertainty, primary care baseline anchors, and outpatient rheumatology hierarchy.

Impact: no locked Batch 1 file is contradicted.

Action required: none before candidate review.

## Batch 2 Consistency Validation

### VERIFIED

Finding: Batch 3 remains consistent with FI-W08 through FI-W13.

Evidence: FI-W14 through FI-W16 react to the established HD1-HD6 hospitalist spine, FI-W12 objective trends, and FI-W13 MAR/action source without replacing or resolving them.

Impact: Batch 2 remains the hospital-course spine and source-type data channel.

Action required: none before candidate review.

### VERIFIED

Finding: FI-W12 values are not overused as answer-file evidence.

Evidence: nephrology and cardiology both use renal, potassium, hemodynamic, and infection trends to support reassessment, but neither treats the values as final medication or discharge decisions.

Impact: objective trends support reasoning without settling Trap #2 or Trap #5.

Action required: later files should preserve this limitation.

### VERIFIED

Finding: FI-W13 actions do not become a final discharge medication plan.

Evidence: all three consultant notes treat MAR actions as inpatient evidence only.

Impact: discharge medication reconciliation remains future work.

Action required: none before candidate review.

## Consultant Defensibility Review

### VERIFIED

Finding: nephrology is defensible.

Evidence: FI-W14 emphasizes recent AKI recovery, potassium risk, blood pressure reserve, intake, and monitoring feasibility while acknowledging the importance of chronic HFrEF/CAD protection.

Impact: nephrology is cautious without being obstructionist.

Action required: none before candidate review.

### VERIFIED

Finding: cardiology is defensible.

Evidence: FI-W15 emphasizes long-term HFrEF/CAD protective therapy, avoidable loss of GDMT, and need for deliberate reintroduction while acknowledging renal/hemodynamic constraints.

Impact: cardiology is proactive without being careless.

Action required: none before candidate review.

### VERIFIED

Finding: endocrinology is defensible.

Evidence: FI-W16 emphasizes chronic prednisone exposure, cautious taper intent, imperfect adherence reconstruction, and adrenal-risk interpretation while rejecting a single hidden endocrine explanation.

Impact: endocrinology is interpretive without becoming the answer key.

Action required: none before candidate review.

## Anti-Answer-File Validation

### VERIFIED

Finding: no Batch 3 file functions as an answer file.

Evidence:

- FI-W14 does not create a final medication restart plan.
- FI-W15 does not create a final GDMT plan.
- FI-W16 does not prove adrenal insufficiency or create a final steroid/diabetes plan.

Impact: multi-document synthesis remains required.

Action required: preserve answer-file discipline during Batch 4 and Batch 5 construction.

## Ratification Carry-Forward Risks

### PLAUSIBLE

Finding: FI-W14 and FI-W15 should be reviewed as a pair.

Evidence: the Cardiology vs Nephrology friction depends on neither consultant becoming obviously correct.

Impact: independent review should test symmetry, timing, and non-finality.

Action required: compare the notes side by side before lock.

### PLAUSIBLE

Finding: FI-W16 should be reviewed for hidden-diagnosis drift.

Evidence: endocrine notes can easily over-resolve steroid uncertainty if they become too definitive.

Impact: candidate review should confirm the file preserves adrenal risk without proving adrenal insufficiency.

Action required: review FI-W16 against FI-W04, FI-W05, FI-W06, FI-W10, and FI-W13.

### NO ISSUE

Finding: Batch 3 preserves closed-world and batch-gated construction doctrine.

Evidence: only FI-W14 through FI-W16 and this validation review were created. No FI-W17 through FI-W22, task-level files, supplementary files, prompts, goldens, grader guidance, AutoQC responses, DOCX artifacts, or submission materials were created.

Impact: phase boundary remains intact.

Action required: stop before Batch 4.

### DISPUTED

Finding: Batch 3 should not decide final discharge medication recommendations or final steroid taper.

Evidence: locked construction plan prohibits answer-file drift. Consultant notes are recommendations and interpretations, not final discharge plans.

Impact: adding final recommendations would damage Trap #1, Trap #2, and Trap #5.

Action required: keep final medication reconciliation, final taper, final disposition, and final discharge-facing synthesis deferred.

## Final Status

Batch 3 Synthetic World-Level File Construction

Files Constructed:

FI-W14 through FI-W16

Status: CANDIDATE REVIEW
